S&P 500   4,282.14 (+0.19%)
DOW   33,981.22 (+0.00%)
QQQ   330.36 (+0.57%)
AAPL   174.89 (+0.19%)
MSFT   291.15 (-0.06%)
META   175.39 (+0.31%)
GOOGL   120.82 (+1.06%)
AMZN   142.51 (+0.29%)
TSLA   910.07 (-0.21%)
NVDA   187.70 (+2.37%)
NIO   19.97 (-0.55%)
BABA   90.78 (+1.13%)
AMD   101.03 (+2.81%)
MU   63.16 (+2.50%)
T   18.46 (+0.22%)
CGC   3.79 (-6.65%)
F   16.20 (+1.06%)
GE   79.51 (-0.51%)
DIS   123.04 (+0.19%)
AMC   19.41 (-9.13%)
PYPL   100.34 (+0.93%)
PFE   48.76 (-1.04%)
NFLX   245.84 (+1.94%)
S&P 500   4,282.14 (+0.19%)
DOW   33,981.22 (+0.00%)
QQQ   330.36 (+0.57%)
AAPL   174.89 (+0.19%)
MSFT   291.15 (-0.06%)
META   175.39 (+0.31%)
GOOGL   120.82 (+1.06%)
AMZN   142.51 (+0.29%)
TSLA   910.07 (-0.21%)
NVDA   187.70 (+2.37%)
NIO   19.97 (-0.55%)
BABA   90.78 (+1.13%)
AMD   101.03 (+2.81%)
MU   63.16 (+2.50%)
T   18.46 (+0.22%)
CGC   3.79 (-6.65%)
F   16.20 (+1.06%)
GE   79.51 (-0.51%)
DIS   123.04 (+0.19%)
AMC   19.41 (-9.13%)
PYPL   100.34 (+0.93%)
PFE   48.76 (-1.04%)
NFLX   245.84 (+1.94%)
S&P 500   4,282.14 (+0.19%)
DOW   33,981.22 (+0.00%)
QQQ   330.36 (+0.57%)
AAPL   174.89 (+0.19%)
MSFT   291.15 (-0.06%)
META   175.39 (+0.31%)
GOOGL   120.82 (+1.06%)
AMZN   142.51 (+0.29%)
TSLA   910.07 (-0.21%)
NVDA   187.70 (+2.37%)
NIO   19.97 (-0.55%)
BABA   90.78 (+1.13%)
AMD   101.03 (+2.81%)
MU   63.16 (+2.50%)
T   18.46 (+0.22%)
CGC   3.79 (-6.65%)
F   16.20 (+1.06%)
GE   79.51 (-0.51%)
DIS   123.04 (+0.19%)
AMC   19.41 (-9.13%)
PYPL   100.34 (+0.93%)
PFE   48.76 (-1.04%)
NFLX   245.84 (+1.94%)
S&P 500   4,282.14 (+0.19%)
DOW   33,981.22 (+0.00%)
QQQ   330.36 (+0.57%)
AAPL   174.89 (+0.19%)
MSFT   291.15 (-0.06%)
META   175.39 (+0.31%)
GOOGL   120.82 (+1.06%)
AMZN   142.51 (+0.29%)
TSLA   910.07 (-0.21%)
NVDA   187.70 (+2.37%)
NIO   19.97 (-0.55%)
BABA   90.78 (+1.13%)
AMD   101.03 (+2.81%)
MU   63.16 (+2.50%)
T   18.46 (+0.22%)
CGC   3.79 (-6.65%)
F   16.20 (+1.06%)
GE   79.51 (-0.51%)
DIS   123.04 (+0.19%)
AMC   19.41 (-9.13%)
PYPL   100.34 (+0.93%)
PFE   48.76 (-1.04%)
NFLX   245.84 (+1.94%)
LON:STX

Shield Therapeutics - STX Share Forecast, Price & News

GBX 9.10
+0.15 (+1.68%)
(As of 08/18/2022 04:35 PM ET)
Add
Compare
Today's Range
8.76
9.10
50-Day Range
5.70
14.50
52-Week Range
5.52
52
Volume
671,717 shs
Average Volume
801,142 shs
Market Capitalization
£19.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
STX stock logo

About Shield Therapeutics (LON:STX) Stock

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

Shield Therapeutics Trading Up 1.7 %

LON:STX traded up GBX 0.15 ($0.00) during trading hours on Thursday, hitting GBX 9.10 ($0.11). The company had a trading volume of 671,717 shares, compared to its average volume of 801,142. The company has a market capitalization of £19.67 million and a PE ratio of -1.03. The stock has a 50-day moving average price of GBX 8.80 and a 200 day moving average price of GBX 16.43. Shield Therapeutics has a 52 week low of GBX 5.52 ($0.07) and a 52 week high of GBX 52 ($0.63). The company has a debt-to-equity ratio of 0.38, a current ratio of 5.11 and a quick ratio of 4.11.

Receive STX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STX Stock News Headlines

Shield Therapeutics on track; starting to gain traction in the US
Shield Therapeutics on track; says gains traction in the US
Shield Therapeutics : Price Monitoring Extension
See More Headlines
Receive STX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£1.52 million
Cash Flow
GBX 5.66 per share
Book Value
GBX 19 per share

Miscellaneous

Free Float
N/A
Market Cap
£19.67 million
Optionable
Optionable
Beta
N/A

Key Executives

  • Mr. Gregory P. Madison (Age 54)
    CEO & Director
    Comp: $432.57k
  • Mr. Christian Schweiger M.D. (Age 55)
    Ph.D., Co-Founder & Non Exec. Director
    Comp: $50k
  • Mr. Hans-Peter Rudolf
    Chief Financial Officer
  • Ms. Lucy Huntington-Bailey
    Gen. Counsel & Company Sec.
  • Ms. Suzanne Wood
    Group HR Director
  • Ms. Carol Akinola
    Head of Pharmacovigilance & Medical Information
  • Dr. José A. Menoyo M.D.
    Chief Medical Officer













STX Stock - Frequently Asked Questions

How have STX shares performed in 2022?

Shield Therapeutics' stock was trading at GBX 44.50 at the beginning of the year. Since then, STX shares have decreased by 80.2% and is now trading at GBX 8.81.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of Shield Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta PLC (CPT.L) (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and SkinBioTherapeutics (SBTX).

What is Shield Therapeutics' stock symbol?

Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."

How do I buy shares of Shield Therapeutics?

Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Shield Therapeutics' stock price today?

One share of STX stock can currently be purchased for approximately GBX 8.81.

How much money does Shield Therapeutics make?

Shield Therapeutics (LON:STX) has a market capitalization of £19.05 million and generates £1.52 million in revenue each year.

How can I contact Shield Therapeutics?

Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The official website for the company is www.shieldtherapeutics.com. The company can be reached via phone at +44-191-5118500.

This page (LON:STX) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.